<p><strong>佳兆业健康集团有限公司</strong> (HKG:876) 的股票在过去一个月继续保持其近期的势头，涨幅达 27%。过去 30 天的表现是该股票在过去一年中 323% 涨幅的锦上添花，实在是令人瞩目。</p>
<p>即便在如此大幅的价格上涨之后，佳兆业健康集团的市销率（&#34;P/S&#34;）为 2.8 倍，相较于香港医疗设备行业，仍可能看起来像是一个买入机会，因为该行业约一半的公司市销率超过 5.2 倍，甚至超过 10 倍的市销率也相当普遍。然而，我们需要更深入地探讨，以确定降低的市销率是否有合理的依据。</p>
<p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
<p>查看我们对佳兆业健康集团的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/4509014-ps-multiple-vs-industry-1-dark-2/1768090294134?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/4509014-ps-multiple-vs-industry-1-dark-2/1768090294134"/></p>
<p>SEHK:876 市销率与行业比较 2026 年 1 月 11 日</p>
<h3>佳兆业健康集团的市销率对股东意味着什么？</h3>
<p>例如，考虑到佳兆业健康集团最近的财务表现不佳，其收入一直在下降。或许市场认为最近的收入表现不足以跟上行业，导致市销率受到影响。然而，如果这种情况没有发生，那么现有股东可能会对股价未来的走势感到乐观。</p>
<p>我们没有分析师的预测，但您可以通过查看我们关于佳兆业健康集团的 <strong>免费</strong> 报告，了解最近的趋势如何为公司未来铺路，包括收益、收入和现金流。</p>
<h2>佳兆业健康集团是否有收入增长的预测？</h2>
<p>为了证明其市销率的合理性，佳兆业健康集团需要实现低迷的增长，且增长速度落后于行业。</p>
<p>回顾过去一年，公司收入出现了令人失望的 8.5% 的下降。因此，三年前的收入总体也下降了 17%。因此，可以公平地说，最近的收入增长对公司来说是不可取的。</p>
<p>与行业相比，行业预计在未来 12 个月内将实现 43% 的增长，而公司基于最近中期收入结果的下行趋势则显得格外严峻。</p>
<p>考虑到这一点，我们理解为什么佳兆业健康集团的市销率低于大多数行业同行。然而，随着收入的下滑，市销率是否已经触底并没有保证。即使只是维持这些价格，在最近的收入趋势已经对股价造成压力的情况下，也可能很难实现。</p>
<h2>我们可以从佳兆业健康集团的市销率中学到什么？</h2>
<p>最新的股价飙升并不足以将佳兆业健康集团的市销率拉近行业中位数。我们认为市销率的作用主要不是作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
<p>毫无疑问，佳兆业健康集团在中期收入下滑的背景下维持其低市销率。在这个阶段，投资者认为收入改善的潜力不足以证明更高的市销率。如果最近的中期收入趋势持续下去，在这种情况下，股价很难在短期内强劲波动。</p>
<p>我们不想过于泼冷水，但我们确实发现了 <strong>佳兆业健康集团的 2 个警示信号</strong>（其中 1 个不可忽视！），您需要留意。</p>
<p>如果这些 <strong>风险让您重新考虑对佳兆业健康集团的看法</strong>，请查看我们的高质量股票互动列表，以了解还有哪些其他选择。</p>

佳兆业健康

<p>佳兆业健康集团控股有限公司（HKG:876）在过去一个月的股价上涨了 27%，推动了过去一年 323% 的涨幅。尽管如此，该公司的市销率（P/S）为 2.8 倍，仍然低于行业同行，反映出对收入下降的担忧，去年收入下降了 8.5%。市场对未来收入增长的怀疑，尤其是在行业增长预测为 43% 的背景下，使得市销率保持低迷。投资者保持谨慎，潜在风险影响着市场情绪和股价稳定性</p>

<p><strong>Kaisa Health Group Holdings Limited</strong> (HKG:876) shares have continued their recent momentum with a 27% gain in the last month alone. The last 30 days were the cherry on top of the stock's 323% gain in the last year, which is nothing short of spectacular.</p>
<div class="lb-trans"><p><strong>佳兆业健康集团有限公司</strong> (HKG:876) 的股票在过去一个月继续保持其近期的势头，涨幅达 27%。过去 30 天的表现是该股票在过去一年中 323% 涨幅的锦上添花，实在是令人瞩目。</p>
</div><p>Even after such a large jump in price, Kaisa Health Group Holdings' price-to-sales (or &#34;P/S&#34;) ratio of 2.8x might still make it look like a buy right now compared to the Medical Equipment industry in Hong Kong, where around half of the companies have P/S ratios above 5.2x and even P/S above 10x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.</p>
<div class="lb-trans"><p>即便在如此大幅的价格上涨之后，佳兆业健康集团的市销率（&#34;P/S&#34;）为 2.8 倍，相较于香港医疗设备行业，仍可能看起来像是一个买入机会，因为该行业约一半的公司市销率超过 5.2 倍，甚至超过 10 倍的市销率也相当普遍。然而，我们需要更深入地探讨，以确定降低的市销率是否有合理的依据。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
</div><p>See our latest analysis for Kaisa Health Group Holdings</p>
<div class="lb-trans"><p>查看我们对佳兆业健康集团的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/4509014-ps-multiple-vs-industry-1-dark-2/1768090294134" alt="" original-src="https://images.simplywall.st/asset/chart/4509014-ps-multiple-vs-industry-1-dark-2/1768090294134"/></p>
<p>SEHK:876 Price to Sales Ratio vs Industry January 11th 2026</p>
<div class="lb-trans"><p>SEHK:876 市销率与行业比较 2026 年 1 月 11 日</p>
</div><h3>What Does Kaisa Health Group Holdings' P/S Mean For Shareholders?</h3>
<div class="lb-trans"><h3>佳兆业健康集团的市销率对股东意味着什么？</h3>
</div><p>For example, consider that Kaisa Health Group Holdings' financial performance has been poor lately as its revenue has been in decline. Perhaps the market believes the recent revenue performance isn't good enough to keep up the industry, causing the P/S ratio to suffer. However, if this doesn't eventuate then existing shareholders may be feeling optimistic about the future direction of the share price.</p>
<div class="lb-trans"><p>例如，考虑到佳兆业健康集团最近的财务表现不佳，其收入一直在下降。或许市场认为最近的收入表现不足以跟上行业，导致市销率受到影响。然而，如果这种情况没有发生，那么现有股东可能会对股价未来的走势感到乐观。</p>
</div><p>We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our <strong>free</strong> report on Kaisa Health Group Holdings' earnings, revenue and cash flow.</p>
<div class="lb-trans"><p>我们没有分析师的预测，但您可以通过查看我们关于佳兆业健康集团的 <strong>免费</strong> 报告，了解最近的趋势如何为公司未来铺路，包括收益、收入和现金流。</p>
</div><h2>Is There Any Revenue Growth Forecasted For Kaisa Health Group Holdings?</h2>
<div class="lb-trans"><h2>佳兆业健康集团是否有收入增长的预测？</h2>
</div><p>In order to justify its P/S ratio, Kaisa Health Group Holdings would need to produce sluggish growth that's trailing the industry.</p>
<div class="lb-trans"><p>为了证明其市销率的合理性，佳兆业健康集团需要实现低迷的增长，且增长速度落后于行业。</p>
</div><p>Retrospectively, the last year delivered a frustrating 8.5% decrease to the company's top line. As a result, revenue from three years ago have also fallen 17% overall. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>回顾过去一年，公司收入出现了令人失望的 8.5% 的下降。因此，三年前的收入总体也下降了 17%。因此，可以公平地说，最近的收入增长对公司来说是不可取的。</p>
</div><p>Comparing that to the industry, which is predicted to deliver 43% growth in the next 12 months, the company's downward momentum based on recent medium-term revenue results is a sobering picture.</p>
<div class="lb-trans"><p>与行业相比，行业预计在未来 12 个月内将实现 43% 的增长，而公司基于最近中期收入结果的下行趋势则显得格外严峻。</p>
</div><p>With this in mind, we understand why Kaisa Health Group Holdings' P/S is lower than most of its industry peers. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. Even just maintaining these prices could be difficult to achieve as recent revenue trends are already weighing down the shares.</p>
<div class="lb-trans"><p>考虑到这一点，我们理解为什么佳兆业健康集团的市销率低于大多数行业同行。然而，随着收入的下滑，市销率是否已经触底并没有保证。即使只是维持这些价格，在最近的收入趋势已经对股价造成压力的情况下，也可能很难实现。</p>
</div><h2>What We Can Learn From Kaisa Health Group Holdings' P/S?</h2>
<div class="lb-trans"><h2>我们可以从佳兆业健康集团的市销率中学到什么？</h2>
</div><p>The latest share price surge wasn't enough to lift Kaisa Health Group Holdings' P/S close to the industry median. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.</p>
<div class="lb-trans"><p>最新的股价飙升并不足以将佳兆业健康集团的市销率拉近行业中位数。我们认为市销率的作用主要不是作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
</div><p>It's no surprise that Kaisa Health Group Holdings maintains its low P/S off the back of its sliding revenue over the medium-term. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. If recent medium-term revenue trends continue, it's hard to see the share price moving strongly in either direction in the near future under these circumstances.</p>
<div class="lb-trans"><p>毫无疑问，佳兆业健康集团在中期收入下滑的背景下维持其低市销率。在这个阶段，投资者认为收入改善的潜力不足以证明更高的市销率。如果最近的中期收入趋势持续下去，在这种情况下，股价很难在短期内强劲波动。</p>
</div><p>We don't want to rain on the parade too much, but we did also find <strong>2 warning signs for Kaisa Health Group Holdings</strong> (1 can't be ignored!) that you need to be mindful of.</p>
<div class="lb-trans"><p>我们不想过于泼冷水，但我们确实发现了 <strong>佳兆业健康集团的 2 个警示信号</strong>（其中 1 个不可忽视！），您需要留意。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Kaisa Health Group Holdings</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果这些 <strong>风险让您重新考虑对佳兆业健康集团的看法</strong>，请查看我们的高质量股票互动列表，以了解还有哪些其他选择。</p>
</div>

尽管佳兆业健康集团控股有限公司（HKG:876）的股价上涨了 27%，但其收入依然低迷，无法避免